Objectives In pharmaceutical drug development, preclinical tests in animal models are essential to demonstrate whether the new drug is orally bioavailable and to gain a first insight into in vivo pharmacokinetic parameters that can subsequently be used to predict human values. Despite significant advances in the development of bio-predictive in vitro models and increasing ethical expectations for reducing the number of animals used for research purposes, there is still a need for appropriately selected pre-clinical in vivo testing to provide guidance on the decision to progress to testing in humans. The selection of the appropriate animal models is essential both to maximise the learning that can be obtained from such experiments and to avoid unnecessary testing in a range of species. Key findings The present review, provides an insight into the suitability of the pig model for predicting oral bioavailability in humans, by comparing the conditions in the GIT. It also contains a comparison between the bioavailability of compounds dosed to both humans and pigs, to provide an insight into the relative correlation and examples on why a lack of correlation may be observed. Summary While there is a general trend towards predicting human bioavailability from pig data, there is considerable variability in the data set, most likely reflecting species specific differences in individual drug metabolism. Nonetheless, the correlation between pigs vs. humans was comparable to that reported for dogs vs. humans. The presented data demonstrate the suitability of the pig as a preclinical model to predict bioavailability in human.
Introduction
In pharmaceutical drug product development, selection of the best lead drug candidate, defining how to formulate and to develop it into a newly licensed medicine, is a complicated, costly and risky process. [1] Over the last few decades, despite huge advances in therapeutic target discovery and the number of drug molecules entering development programs, the number of drug products (i.e. medicines) licensed for clinical use has decreased consistently. [2] Thus, there is a clear need to develop new technologies to improve the developability of emerging drug candidates and to unlock key bottlenecks stifling innovation in pharmaceutical development. New methods of reliably assessing the quality, safety and efficacy of emerging medicines are required to drive change in the drug product development process from the traditional 'trial and error' testing approach to select the most appropriate tests and avoiding costly development delays. Introducing more clinically relevant testing methods will make drug product development more cost-effective, reduce unnecessary testing and ultimately facilitate earlier access to market for new medicines. This strategy towards more reliable preclinical testing has parallels with the recently proposed biopharmaceutics risk assessment roadmap (BioRAM) for optimising drug product development and clinical performance. [3] A key tenet of the BioRAM approach is to move from a 'test and confirm' to a 'learn and confirm' development paradigm, where predictions will be made in the 'learn phase' on how to maximise medical value for a new drug in advance of in vivo studies, and in vivo studies become 'confirmatory' rather than 'exploratory'.
Operating within the conventional drug product development paradigm involves initially in vitro screening, preclinical testing followed by clinical evaluation in humans. There are two key stages where improvements in applying a 'learn and confirm' paradigm could be sought. Firstly, for the link between the in vitro testing and the preclinical evaluation in vivo, there is a need for an improved bio-relevance of screening conditions that truly reflect the preclinical animal model conditions, so the preclinical in vivo testing becomes confirmatory of in vitro tests. Secondly, there is a need to validate the reliability of preclinical models to predict performance in humans so that clinical studies become truly confirmatory of preclinical investigations.
When attempting to make a priori prediction whether a new drug product will be bioavailable in vivo, a thorough understanding of the factors influencing drug absorption is essential. However, the process of oral drug absorption is complex, which is influenced by numerous factors including (1) the physiochemical properties of the drug, (2) formulation-related factors such as formulation type and excipients used and (3) physiological, genetic, biochemical and pathophysiological factors in the gastrointestinal (GI) tract. While the utility of bio-relevant in vitro and in silico models for predicting absorption potential, based on physiochemical properties of the drug substance, is well established, there are gaps in our knowledge on the interplay of drug, gastrointestinal physiology and formulation excipients on in vivo drug absorption. These gaps limit the ability to reliably predict in vivo behaviour for formulated drug products. Therefore, preclinical in vivo assessment of prototype drug formulations is routinely required, involving potentially a range of preclinical animal species, such as rats, dogs, pigs and non-human primates.
When considering the most suitable animal model to predict bioavailability or bio-performance in humans, a detailed understanding of physiological, anatomical and biochemical differences between different animal models is required. [4] In preclinical ADMET studies, commonly two animal species are used -one rodent and one non-rodent. There are limiting factors in the use of rodent species as an animal model to investigate the impact of drug formulation on bioavailability, such as the small liquid volume in the gastrointestinal tract, [5] limited dose size and the generally higher metabolic rate, [6] where the latter may also provide an obstacle for reliably predictions of human pharmacokinetics. The most common rodent model is the rat. Rats are considered to be good predictors of intestinal permeability in humans and have been shown to display similar intestinal absorption profiles (i.e. correlation >0.8 between permeability estimates in rat and humans for 16 compounds encompassing both passive and carrier-mediated substrates) and similar transporter expression patterns in the small intestine. [7] However, there are major differences between the two species that limit the utility of rats for predicting bioavailability in humans, including distinct expression levels and patterns for metabolising enzymes in the intestine, and anatomical differences such as size, gastrointestinal length, pH profile and transit time. [7] There have been extensive discussions in the literature on the use of dog and non-human primate models to predict oral bioavailability in humans and the merits of preclinical models have been well described recently. [8, 9] In principle, non-human primates are considered the closest model to humans, notwithstanding discrepancies with respect to intestinal metabolism which have been recently reviewed. [8] However, apart from ethical considerations for using non-human primates for routine preclinical testing, studies involving non-human primates are prohibitively expensive. Dogs have traditionally been the most commonly used large animal model in pharmaceutical drug product development. However, there are notable differences in the gastrointestinal tract relative to humans that must be considered. [10] The pH in the fasted state canine stomach is considered to be on average higher and more variable than in humans, ranging between 1.5 and 6.8. As a result, it is common to pre-dose dogs with pentagastrin, whereby gastric pH is lowered.
In contrast, there is much less published information on the suitability of pigs for assessing bioavailability of oral drug products. The use of pigs in preclinical assessments has increased in recent years. [11, 12] A principle advantage of the pig model is the similarity between gastrointestinal tract anatomy and physiology of humans and pigs. [13, 14] Pigs, like humans, are omnivorous, [15] they have similar digestive system [4, 6, 15] and they are a suitable model for evaluation of most ADMET endpoints. [16] Moreover, the intestinal microbiome of the colon and the digestion characteristics of the small intestines are considered to be similar to man. [17] Analogies among pigs and human include skin structure, cardiovascular system, urinary system as well as the immune system. [13] There are several breeds of pigs used in pharmaceutical research, ranging from the domestic Landrace (LR) to more selectively bred miniature-sized pigs, such as G€ ottingen, Yucatan, Hanford, Sinclair minipigs. G€ ottingen minipigs are the most commonly used, and were originally developed by crossbreeding the Minnesota minipig, Vietnamese potbelly pig and German Landrace pig. [18] While there are gaps in the literature on the possible breed-specific difference in gastrointestinal physiology, the mostly widely characterised are the LR and G€ ottingen minipig. [19] In summary, with the increasing emphasis on expediting drug product development (or a 'quick win, fast fail' paradigm), drug development scientists must operate in reduced time-lines to provide a drug formulation that provides efficient and reliable bioavailability in vivo. Selecting the most suitable preclinical animal model is essential to demonstrate the efficacy of the drug formulation in vivo and to provide early predictors of the likely performance in humans. While the merits and limitations of rat, dog and non-human primate models have been extensively reviewed in the literature, the purpose of this review is to focus on the pig and its suitability as a model in drug product development. Furthermore, an extensive review of the literature was completed to harness knowledge from previous studies involving bioavailability assessment of drugs in pigs with the objective of assessing the degree of correlation between human's and pig's bioavailability, which to the best of our knowledge have not been published elsewhere. A secondary goal of this work was to compare the pig model to the more commonly used dog model, which will facilitate the more critically informed decisions on which preclinical species to select in drug product development.
Comparing the gastrointestinal tract of pigs and humans
To determine the suitability of the pig for pharmacokinetic studies, an understanding of the conditions in the GI tract is essential. Differences in the anatomical and physiological characteristics of the GI tract can impact formulation performance and drug absorption. The next section will directly compare the pig to human GI tract conditions with the focus on identifying key differences.
Gastrointestinal pH
The impact of the GI pH on oral drug absorption in humans is well established by affecting parameters such as solubility, ionisation and stability. [20] In particular, the acidic pH of the stomach can have a significant influence on drug product performance, particularly for drugs displaying pH-dependent solubility. The gastric pH during the fasted state in pigs and humans is broadly similar, for example the stomach pH in the fasted pig is 1.2-4.0, [21] compared to reported ranges for humans, of 1.0-3.5. [22] A more detailed overview of the pH along the length of the GI tract is presented in Table 1 which demonstrates a similar increase in the pH pattern in the small intestine and a pH reduction in the colon compared with humans. Interestingly, the pH profiles between pigs and humans in both the fasted and fed states were comparable. This is one distinct advantage of the porcine model vs the canine model and particularly important in terms of suitability of the pig model for predicting the performance of drug dosage forms that are likely to be influenced by the pH. This is pertinent for modified release dosage forms, where a pH change can act as a trigger for drug release in the intestinal lumen, for example, gastric-resistant tablets or colonic delivery based upon a pH-sensitive polymer.
Intestinal physiology
While there are external morphological differences between humans and pigs, their internal physiology is considerably similar. [4, 15, 26] At maturity, the total length of the pig intestine is reported to be longer in pigs (24 cm/kg [26] ) compared to the human intestine which is estimated to be 14 cm/kg. However, the reported values of total GI tract length vary widely in pigs, with values as much as 23 m in length, depending on the size and weight of the pig, as well as the type of measurement technique employed in various studies. [4, 15, 26] Furthermore, the anatomical arrangement of the large intestine is different between pigs and humans. In humans, the large intestine can be described in ascending, transverse and descending colon forming a square-like configuration, which ends in the s-shape of the sigmoid colon. [15] In pigs, the large intestine is described as a spiral colon, where the distinct sections of the colon are arranged in a series of coils. [13, 15] Despite these differences, the relative length of each of the three major intestinal segments (as a % of overall length) is similar between pigs and humans, as illustrated in Figure 1 . Merchant et al. [4, 26] demonstrated that the length of each section in pigs with an average weight of 95-110 kg is comparable to humans, comprising 82%, 17%, 1% vs 65%, 33% and 2.5% for the small intestine, colon and caecum, respectively. Normally, smaller pigs are used in preclinical studies; therefore, it is interesting to note that similar studies in smaller landrace [23, 24] Fed pH [4, 24] Fasted pH [25] Fed pH [25] Fasted pH [4,21]b Fed pH [26] pigs (average weight 18 kg) showed that the intestinal sections are also relatively similar. Differences in relative % lengths of the GI tract could potentially influence the type of formulation to be studied in a pig model. Merchant et al. [26] reported that the amount of water in the pig intestine (18 g/kg body weight) was higher than in human intestine (8.2 g/kg body weight). A greater amount of water within the porcine intestinal tract may also merit consideration in terms of the dosage form disintegration and potential impact on drug dissolution.
Given that the surface area available for drug absorption is a critical factor for passive diffusion across the intestinal membrane, a comparison of the surface area of the pig vs human intestine is pertinent (Table 2 ). DeSesso and Williams investigated the absorptive surface area in the lumen of the small intestine of pigs and compared this to human surface area. Using a basic cylindrical estimate of the luminal surface area, of the small intestine of a 70 kg human vs a 47 kg pig, the pig's intestinal surface area appears to be higher than the human's area, at 1.4 m 2 vs 0.42 m 2 , respectively. However, given that the apical 'brush border' on enterocytes of both humans and pigs is composed of pilicae, villi and micro-villi, a more accurate estimate of the total surface area that take these factors in account, suggested that the intestinal absorptive surface area of humans and pigs are comparable, at 252 m 2 and 168-210 m 2 , respectively. [27] Bile composition Bile salts are amphiphilic molecules and intrahepatic bile acids undergo further conjugation with glycine and taurine. [28] Once synthesised and conjugated in the hepatocyte, bile acids are transported into the biliary tract, secreted through the hepatic duct into the gallbladder. During food intake, the bile fluid is secreted into the duodenum, mediated by cholecystokinin and secretin. [29] In some animal species, bile is secreted continuously (e.g. rats), whereas pigs have a secretion pattern similar to humans. [4, 30] Once secreted into the intestine, the central function of bile acids is the solubilisation of dietary lipids and promotion of their digestion and absorption. Thus, bile salts can have a significant influence on drug absorption, and in particular promote the solubilisation of poorly water-soluble drugs. [31] Bile acids can be classified into primary and secondary bile acids; chenodeoxycholic acid and cholic acid are primary bile acids in many species, including pigs and humans. [32] Secondary bile acids are formed by bacterial hydrolysis of conjugated bile acids in the large intestine. The major bile acids present in pigs and humans are summarised in Table 3 and a comparison of the bio-synthesis pathway for bile salts between the two species is presented in Figure 2 . A key difference between bile composition between pigs and humans is hyocholic acid, which is the major primary bile acid in pigs. Hyocholic acid is synthesised in pigs by 6a-hydroxylation of chenodeoxycholate, [32] whereas in humans only small amounts of hyocholic acid and hyodeoxycholic acid exist. [33, 34] In humans, CYP3A4 has been identified as the relevant enzyme for the 6a-hydroxylase reaction of hyocholic acid biosynthesis. [35] In pigs, the primary structure of the porcine 6a-hydroxylase enzyme showed 75% identity with members of the CYP4A subfamily in human. [32] Figure 1 Relative gastrointestinal (GI) length [%] of sections of the GI tract from: published pig (crossbreed of Large White and Landrace)* [26] and human data [4, 27] ; in comparison to LR (unpublished data) **. In both humans and pigs, the major bile components are conjugated with taurine or glycine, [36] with the majority (~80%) being conjugated with glycine. [37] In pigs, the rank order of prevalence of bile salts in the intestine is glycohyoycholate (44.4%), glyco-chenodeoxycholate (31.2%), glycol-hyodeoxycholate (8.2%), tauro-hyocholate (6.8%) and tauro-chenodeoxycholate (6.6%), as illustrated in Figure 3 . [38, 39] By comparison, the most prevalent intestinal bile salts in humans are glyco-cholate (36.5%), glycolchendeoxycholate (33%), glyco-deoxycholate (10%), taurocholate (6.8%) and tauro-chendeoxycholate (6.7%).
Given the key role bile acids play in the drug absorption process, it is still unclear what impact, if any, these compositional differences in bile have on drug absorption. Also given that bile composition is highly influenced by fasted and fed states in humans, there is a need to improve knowledge on bile secretion profiles in the fasted and fed porcine intestine. Figure 2 Conversion of cholesterol into primary and secondary bile acids, adapted scheme from Ref. [32] . [Colour figure can be viewed at wile yonlinelibrary.com] Figure 3 Rank order of prevalence of bile salts. (a) Pigs, GHC, glyco-hyocholate; GCDC, glyco-chenodeoxycholate; GHDC, glyco-hyodeoxycholate; THC, tauro-hyocholate; TCDC, tauro-chenodeoxycholate; based on the reported data from Scanff et al., [40] (b) human bile salts, GC, glycocholate; GCDC, glyco-chenodeoxycholate; GDC, glyco-deoxycholate; TC, tauro-cholate; TCDC, tauro-chendeoxycholate. [38] Gastrointestinal transit time
Formulations that enter the GI tract must pass through several sections, of which some are specialised for absorption and others for holding and digesting food. The stomach is used for holding food and therefore can delay transit through the small intestine. The small intestine is the main absorptive site of drugs and nutrients in both pigs and humans. A comparison of the different transit times through the sections is crucial to increase the understanding of the pig as a preclinical animal model. The small intestine transit time is the most important time for drug absorption during the GI tract, and it is reported to be similar in pigs and humans, 3-4 h in pig compared to 2-4 h in humans. [6, 10, 41] As described in previous sections, the physiology of the small intestine is also comparable; consequently, the drug absorption in the small intestine in pigs is thought to be similar to the absorption in humans.
The gastric emptying time is an issue which has received much discussion when considering the suitability of pigs for assessing oral pharmacokinetics. The gastric emptying rate in pigs is considered to be longer and more variable than in humans. Human gastric transit is reported to be 10-15 min for liquids and can be up to 2 h for indigestible solids. [24] By comparison, reported values of gastric emptying in pigs display wide variability. This may reflect a physiological difference of the stomach of pigs, which has a muscular outpouching called the torus pyloricus that can cause food to be retained in the stomach for prolonged period of up to 24 h. [15] Alternatively, methodological differences in how the gastric emptying rate is determined can lead to variable estimates. Hossain et al. [21] reported an extraordinary long and highly variable gastric emptying time of 1-28 days measured by the emptying of a solid dosage form from the stomach. A trend towards an increased gastric emptying time was observed with increasing density of the dosage form. However, this study was limited in that it involved only two pigs that were repeatedly dosed for a prolonged period. In another study, Oberle and Das [25] reported a shorter gastric emptying time in pigs of 6-24 h, albeit still highly variable and longer than comparable values in humans. [21, 25] In contrast, Davis et al. [6] reported that the gastric emptying time after a light meal ranged between 1.5 and 6 h in landrace pigs, and therefore was closer to human estimates, based upon investigations of the gastric emptying of liquids and solid dosage forms in pigs using gamma scintigraphy. [6] Davis et al. [6] also reported the mean time to empty 50% of a dosed liquid to be 1.4 h in pigs, compared to reported estimates of 11-14 min for a solution in man. [42] The gastric emptying rate of pellets in pigs (pellet size of 0.85-1.4 mm) was 2.2 h for 50% of the pellets to enter the small intestine and 4 h after dosing a non-disintegrating tablet. [6] The small intestinal transit time in the pigs was reported to be constant on 3-4 h for the three dosage forms (solution, pellets and tablet), the total transit time was between 24 and 48 h for three of the four pigs, and one pig showed an unusually long total transit time of 72-96 h. [6] More recently, Christiansen et al. [43] investigated the possibility of using G€ ottingen minipigs to investigate fasted vs fed state differences in oral bioavailability, and as part of the study, co-administered paracetamol was used as a marker for gastric emptying. Christensen et al. reported gastric emptying rates in the fasted animals to be 4-6 h. After administration of FDA standard breakfast to minipigs (5 or 10 g/kg) or a nutritional drink (10 or 20 g/kg), the gastric emptying rate did not increase, but rather tended to decrease slightly. A possible explanation for this apparent lack of impact of food on gastric emptying may indicate that fasted pigs retain food in the stomach for prolonged periods, and hence are not dosed in a 'truly' fasted state. This hypothesis was further explored by Suenderhauf et al. [44] where pigs were pre-dosed with the pro-kinetic drug metoclopramide, followed by a post mortem determination of the stomach contents weight. In metoclopramide pre-treated pigs, the weight of the stomach contents was lower compared to the non-treated groups, suggesting that this is a potential approach to mimic a fasted state condition. In contrast, however, a recent study by Henze et al. [45] did not observe an effect of pre-treating with metoclopramide on the gastric emptying rate in minipigs, based upon analysis of paracetamol absorption both in the fasted and different fed state conditions (FDA breakfast vs nutritional drink vs normal pig food). The study found that the shortest and most consistent gastric emptying rate was observed in the case where the animals had access to normal pig food at the normal times of the day. It would appear therefore that further studies are required to elucidate whether the pig model is suitable for exploring fasted vs fed effects on oral bioavailability of drug products.
Another factor for consideration in relation to transit time of dosage forms is the age of the pigs. Snoeck et al. [46] compared the investigated transit time of pellets in young suckling piglets to piglets in different post-weaning states. The gastric emptying rate in sucking pigs (3-week old 4-6 kg pigs) was faster compared to post-weaning pigs (4-to 7-week old 10-13 kg pigs), with 75% of the pellets having emptied from the stomach within 1.5-3.5 h. Three days post-weaning, the gastric emptying time is markedly prolonged (75% of the pellets having emptied from the stomach within 25-34 h). This delayed intestinal transit was most likely related to the change in diet (i.e. from sow's milk to a dry diet) and social stress as a result of weaning. Three weeks post-weaning, the gastric emptying rate appeared to return to norm with transit times similar to values reported in growing and adult pigs (75% pellets emptied within 7 h). While the majority of pellets were emptied from the stomach within 24 h in 3-week-weaned pigs,~5% of pellets retained in the stomach 31 h after dose. Furthermore, while transit of pellets in the small intestine and caecum was relatively rapid and complete, prolonged retention of pellets in the colon was also evident (85% pellets excretion within 50.5 h). The authors therefore suggested that for certain types of pelletized dosage forms, extended retention in the porcine stomach and colon may need to be considered. [46] The colonic transit time is highly variable in both pigs and humans. In humans, estimates can range from 20 h to >2 days. [47, 48] Overall, the total gastrointestinal transit time in pigs, measured by roentgenography, was reported to be between 2 and 33 days. [6] Although this would appear longer than in humans, this may also reflect the slow and variable gastric emptying rate as discussed previously.
Given the significant variability observed with transit time as described previously, this may be due to different study protocols used as gastric emptying could depend on their normal feeding cycle, the fasting regime, the age and size of the pigs and amount and type of food. Therefore, a better standardisation of the study protocols would be favourable to obtain more comparable results of the different studies to improve the understanding of the gastric emptying in pigs. Furthermore, the above results from various studies show that further studies with more subjects are needed to get a full understanding of the gastric emptying in pigs. [6, 21, 25, 46] In conclusion, the gastric emptying rate in pigs appears to be slower than in humans, whereas the small intestine transit time in pigs is similar to the ones reported in humans, for solids and liquids. [41] Given that a drug is absorbed in the small intestine and that the area for absorption in pigs is similar to the area in humans, pigs seem to be a suited species for investigation of drug absorption, with the precaution that the plasma sampling should be planned to take the potential slower gastric emptying rate into account.
Intestinal metabolism and transporters
Another key consideration that can affect oral bioavailability is the prevalence of intestinally mediated first-pass metabolism and/or efflux which can collectively limit drug access to the systemic circulation. [49] In humans, it is known that CYP3A enzymes are responsible for metabolising approximately 48% of the drugs currently on the market and account for more than 70% of CYP enzymes present in the GI tract. [50, 51] Therefore, any differences in expression levels of intestinal enzymes and efflux transporters between humans and pigs may have a profound effect on the predictability of drug absorption in humans.
While there are some data published in the literature regarding the expression profiles of important drug transporters (e.g. P-glycoprotein) and metabolising enzymes (e.g. CYP3A) in the GI tract of preclinical animals, the available data are limited. In the cases where these systems are involved in the metabolism or transport of certain drugs, a difference between humans and the animal models can be used to explain a lack of correlation between the species. For example, Cao et al. compared the transporter expression and metabolic enzyme expression in the duodenum between rat and human. The expression profile of 16 intestinal transporters displayed a moderate correlation (r 2 = 0.56), whereas no correlation was found for the expression of metabolising enzymes between rat and human intestine. [7] This suggests a difference in intestinally metabolic capacity between the two different species and the challenges in predicting oral bioavailability in human. Relative to the more commonly utilised rat and dog models, studies reporting expression levels of intestinal transport/metabolising enzymes in pigs are sparse. With respect to the nutritional transporters, Nøhr et al. [52] have demonstrated the presence of the proton coupled amino acid transporter (PAT1) in the small intestine and rectum in minipigs, a transporter also present in the human small intestine. [53] The level of PAT1 expression has, however, to the best of our knowledge, not been quantified in minipigs. In general, the extent of homology between pigs and humans with respect to intestinal drug metabolising enzymes, efflux and influx transporters on both a qualitative and a quantitative level is unclear. Therefore, further mechanistic studies are required to identify inter-species commonalities and differences in transporter and/or metabolic profiles.
Hepatic metabolising enzymes
There are several families of CYP enzymes, each of which have subfamilies and unique isoforms. CYP isoforms are only found in one species, so a specific isoform of humans may have an orthologue in pigs, but an identical isoform is not found to date. [54] CYP3A in humans is the most important enzyme family metabolising around 27% of drug compounds and comprising 30% of the total CYP System. [55] The enzyme seems relatively well conserved in pigs and shows a very high similarity with the CYP3A4 in humans. [56] In particular, it seems that there are no major differences among CYP1A1, 1A2, 2B, 2E1 and 3A in pigs when compared to humans. [57] Hence, the pig may be a suitable preclinical model for drugs that are mainly metabolised by these CYP enzymes. In contrast, the pig model is less suited for studies involving drugs that are metabolised by CYP2C and CYP2D. In humans, the CYP2C and CYP2D metabolise about 22% and 12% of the drugs, respectively. [55] However, porcine CYP2C and CYP2D display a distinctly different substrate specificity. A human CYP2C substrate, S-mephenytoin, was not metabolised by the pig, using liver microsomes. Furthermore, diclofenac and tolbutamid, two CYP2C substrates in humans, [58] were metabolised to a lower extent in pigs compared to humans. [57, 59] The CYP2D activity generally seems higher in pigs than in humans. [25, 29, 60, 61] It is also worth considering that the various pig breeds may display different activity of hepatic enzymes. As recently reviewed, the Landrace pig demonstrated a presence and activity of CYP2D6 and CYP2C9 enzymes, whereas G€ ottingen minipigs showed no activity of CYP2D6 and CYP2C9 enzymes. [54] Oral bioavailability of drugs: comparing pigs vs humans
To assess how well pig and human bioavailability correlate, a systematic review of the published literature was performed to identify previous studies where absolute bioavailability of drugs in pigs has been reported. Studies and compounds were only included where both oral and intravenous data were available; hence, the absolute bioavailability could be calculated. Data from various pig breeds were included. The determination of absolute bioavailability was based on the traditional comparison between the area under the curve (AUC) after intravenous and oral administration:
In total, 20 compounds were identified to fulfil these criteria and the pharmacokinetic data for each compound in pigs and humans are summarised in Table 4 . The degree of correlation of F abs between the pig and human data is presented in Figure 4 . A general positive trend towards predicting human bioavailability based on values in pigs was obtained, with a coefficient of determination r 2 of 0.36. Looking at the individual drug level, the bioavailability in pigs is comparable to that in humans for the majority of drugs. However, there are specific drugs where the oral bioavailability data in pigs differed substantially from human data, which lowered the correlation observed overall between humans and pigs. On closer examination of this latter set, metoprolol and diclofenac appeared to display substantial differences in pigs relative to humans. This is most likely reflecting the different metabolic pathways for these drugs between the two species. Absolute oral bioavailability of metoprolol in pigs was reported to be as low as 3%, whereas the buccal administration leads to a bioavailability of 58-107%. [29] These findings were in accordance with data published by Mogi et al., [61] who could not detect the plasma concentration of metoprolol after oral administration to pigs, as the plasma concentration where under the quantitation limit of the used bioanalysis. In humans, the bioavailability of metoprolol is approximately 50%, a difference suggested to be driven by a difference in the metabolic pathway between the species. Metoprolol undergoes a-hydroxylation and O-demethylation through interactions with CYP2D6. As previously described, CYP2D has a higher activity in pigs than in humans; hence, this difference most likely reflects extensive first-pass metabolism of metoprolol in pigs. Interestingly, metoprolol bioavailability improved substantially to 58-107% following buccal administration to pigs, which supported the observations that first-pass metabolism is the major limiting factor of metoprolol bioavailability in pigs. [29] Mogi et al. reported in vitro data of the oxidation process of metoprolol by liver enzymes from pigs and humans. The O-demethylation process of metoprolol was 10-fold faster by the pig microsomal system when compared to human liver microsomal system. This phenomenon is also reported for other compounds that are metabolised by CYP2D6, like dextromethorphan which shows a rapid and extensive metabolism in the pig and an O-demethylation process that is a 10-fold greater in pig liver microsomes compared to human liver microsomes. [60] It is important to mention that CYP2D6 metabolises about 12% of all compounds, including b-blocker, antipsychotic as well antidepressant drugs. [54] Differences in the metabolic rate may also go in the other direction, that is, humans metabolising faster than pigs. Diclofenac is a CYP2C substrate. Oberle and Das [25] observed a higher bioavailability in pigs compared to human data, which was concluded to be a reflection of a different metabolism profile between the two species. Collectively, these examples underline the importance of looking at the hepatic metabolism when selecting the non-clinical species, but also provide an explanation why quantitative predictions and degree of correlations between pigs and humans is low (r 2 = 0.36). In general, a head-to-head comparison of bioavailability across species may be difficult.
Similar correlations comparing human bioavailability to other preclinical animal species have been described in the literature. Musther et al. [63] investigated the correlation of bioavailability data from dog, monkey, mouse and rat with human bioavailability data. The correlation was conducted based upon a published data-set from Sietma [64] where data from these animal models were reported. The data visualised the breadth of difference that exist between animal species and humans in terms of oral bioavailability. Musther et al. [63] highlighted the gaps in the correlation between the bioavailability in animals and humans and concluded that a quantitative prediction was not possible when comparing the bioavailability head to head. The extent of correlation was for monkey (r 2 = 0.69, 40 drugs), [7, 9, 63, 65] Based on the findings in the current study, the porcine model displayed a higher overall correlation than both rodent models. The porcine model also compares favourably to the canine model, in terms of a similar coefficient previously reported for dogs. It should be noted that the number of drugs available with absolute bioavailability in pigs was lower (20) relative to the other species, reflecting key knowledge gaps in the literature and a need for further investigations to demonstrate more conclusive relationship. Moreover, sorting the data to exclude justifiable outliers, such as the species-specific CYP2D metabolic difference could facilitate more informed conclusion. For example, excluding the values of Diclofenac and Metoprolol, which are two substances not suitable in the pig model, from the correlation illustrated in Figure 4 , improved the correlation from r 2 = 0.36 to r 2 = 0.52. Additionally, to provide an insight on how the rate of drug absorption compares between pigs and humans, t max values were compared. Previously, t max has been used to evaluate gastric emptying, as a delayed emptying leads to a longer t max . [43] Within the group of drugs presented in Table 4 , t max values were reported for only 12 of these drugs. T max values in pigs ranged from 0.6 to 5.0 (median 2.0), whereas in humans the range of t max values was 0.25-2.5 (median 1.9). The larger range of t max values in pigs compared to humans most likely reflects a more variable gastric emptying in pigs, as discussed previously. Figure 5 illustrates the t max ratio between pigs and humans for each drug. As a general guide, t max in pigs was on average 2-fold higher than the corresponding value in humans. While there are individual drugs which do not follow this general guide, such as Ketoprofen where t max was 5-fold higher in pigs, and omeprazole was 4-fold higher in humans, [73] these individual cases most likely reflect species-specific differences in drug metabolism leading to extremes t max estimates. It should also be noted that while t max is useful in the evaluation of gastric emptying, there are limitations to its reliability as an estimate of rate of drug absorption. Differences in fasting/fed state conditions in the study design could affect gastric emptying and therefore need to be tightly controlled to ensure that appropriate comparisons can be made. In addition, the value of t max is highly influenced by the frequency of sampling within the study, and ideally most frequent sampling should be conducted near the expected peak plasma concentrations. The findings presented here would indicate that when designing plasma sampling studies involving pigs, frequent plasma sampling may be required for time periods up to two times the expected t max in humans.
Pig vs dog in predicting human bioavailability: how do they compare?
While the extents of correlation obtained for pigs vs humans are comparable to values reported for dogs vs humans, it should be acknowledged that there is a substantially more diverse drug data-set available in the literature for dogs. To more reliably compare between species, the relationships of human bioavailability to both dogs and pigs were evaluated using only drugs which were common to both. In total, a group of 15 drugs (from the 20 drugs of Table 4 ) were identified from the literature where absolute bioavailability was available in dogs, pigs and humans. Figure 6 presents the relationships obtained for these common set of drugs between pigs vs humans and dogs vs humans. For the set of 15 drugs identified, the coefficients Figure 4 Direct correlation between the oral bioavailability in human and pig of the compounds presented in Table 4 . Table 4 .
of determinations obtained for pigs was r 2 = 0.49, whereas for dogs r 2 = 0.35. Within both relationships, specific drugs could be identified where the oral bioavailability data in the animal correlated poorly to human data.
In the case of absorption rate, it has previously been discussed that on average t max was longer in pigs than humans, most likely reflecting a slower gastric emptying in pigs. In the case of dogs, gastric emptying is considered to be more comparable to humans; however, few studies directly compare rates of absorption between the species. Within the group of 15 drugs where both canine, porcine and human data are available, there were only three drugs were a direct comparison of t max was possible. T max of moxifloxacin was 2.0 AE 1.9, 4.0 AE 1.0 and 1.6 AE 2.9 h in humans, pigs and dogs, respectively, confirming that while dogs and humans are similar, absorption in pigs appear to be marginally slower. [66] A similar trend is evident for ketoprofen with t max values of 0.8, 3.9 AE 1.1 and 1.1 AE 0.3 h in humans, pigs and dogs, respectively. [72, 73] In the case of diclofenac differences are also prominent, a t max of 0.3, 0.8 and 1.2 AE 0.6 h was reported for humans, pigs and dogs, respectively. [25, 62] In summary, while the number of drugs in the data-sets is limited, the findings demonstrate that pigs compare more favourably than dogs at predicting the extent of absolute bioavailability (F abs ) in humans, based on this limited set of comparable studies. The presented data therefore provide further evidence of the suitability of the pig in preclinical assessment of oral dosage forms. However, the rate of drug absorption in pigs is tending to be slower in pigs than humans, whereas in dogs, t max is more comparable to human estimates. In the case of drugs and/or formulations where a delayed rate of absorption might have a significant impact on in vivo performance (e.g. sustained release products or fast acting dosage forms), the canine model may offer advantages, notwithstanding the clear limitation where canine gastric pH is considerable higher than humans and pigs.
The use of the pig model for assessing in vivo performance of oral dosage forms
In drug formulation development, it is crucial to assess the bioavailability of orally delivered drugs and in particular how this can be influenced by the use of different formulations in order to support the formulation development work. Conductance of preclinical in vivo studies as well as in vitro and in silico approaches are often used in combination to understand the mechanisms that drive the absorption from the formulations tested before they are brought into human trials. Optimising the steps from the in vitro work in the lab, linked to in vivo data from the animal studies can therefore help to expedite the process of development.
The most common preclinical models to assess oral dosage forms, include rats, dogs, pigs and less frequently non-human primates. Knowing which preclinical model to use to being able to compare different formulations as well as to predict oral bioavailability in humans is an important decision to generate data where conclusions can be drawn and the right formulation selected and taken into clinical trials in humans. However, there remains a lack of clarity in species selection for a specific formulation technology. This lack of clarity is particularly problematic for drug substances displaying low solubility and/or permeability (i.e. BCS Class II and IV), which generally requires bio-enabling formulations to improve oral bioavailability. While there are numerous oral drug-delivery platform technologies to enhance oral bioavailability, it becomes increasingly clear that each formulation technology cannot be universally applied to all poorly water-soluble drugs and the selection of the correct formulation technology is often complicated (Figure 7) . As a result, a key question that needs to be addressed in selecting the most suitable preclinical model is: Which animal model will reliably predict the in vivo Figure 6 Direct correlation of oral bioavailability: human versus dog and human versus pig, for 15 compounds presented in Table 4 .
performance of a selected formulation technology, in particular bio-enabling formulation technology? Table 5 summarises data from different formulation technologies with in vivo data from pigs, which has been reported in the literature. The objective is to summarise where the pig model has been utilised to demonstrate in vivo performance of specific formulation technology, and to act as a guide on which formulation technologies can be assessed using the pig model. Most of the cases identified in Table 5 involve studies using formulation technologies that enhance oral bioavailability of poorly soluble drugs belonging to the BCS class II. Given the increasing number of new drugs in development with solubility limitations, it is only a natural reflection of current focus in pharmaceutical research. The formulation technologies that have been assessed using pigs include micronized and nanosized formulations, as well as hot melt extrusion, lipid-based and mesoporous silica formulation.
The use of lipid-based formulations as an approach to enhance oral bioavailability has increased in recent times. The drug absorption of lipid-and surfactant-based formulations can be affected by a variety of factors including characteristics on dilution in the intestinal fluids, solubilisation capacity of the drug during transit through the intestine, as well as the presence of food. [91, 92] It has been demonstrated that the lipid-based formulations can not only enhance the solubility of the drug in the intestinal fluids, but also enhance the lymphatic uptake of the drug, which circumvents the first-pass metabolism of the drug. This is predominantly present when the drug is given with long-chain triglycerides and the drug has a log P > 5 and a solubility in triglycerides >50 mg/ml, [93, 94] but exceptions also exist from this rule of thumb. [95] There are a variety of factors that must be considered in designing optimal lipidbased formulations, for example the composition (commonly described by the LFCS classification system), the proportion and type of lipid surfactants and/or co-solvents. Upon digestion and the introduction of bile salts, the mixture of drug, lipids, surfactants and cosolvents is undergoing continual changes from an emulsion to lamellar and hexagonal phases and finally generating a pre-absorptive mixed micellar state. Hence, to predict the behaviour of the drug in the GI tract, it is crucial to have an advanced understanding of how the drug is solubilised and in which phases of the colloidal structure in the GI tract it can be found. It is a complex relation between lipid formulation and their pharmacokinetic properties. Several studies using lipid-based formulations have utilised a pig model to assess in vivo performance, see Table 5 . Griffin et al. [96] showed for the lipophilic drug fenofibrate that the pig model was suitable to assess the in-vivo performance of lipid-based formulations, showing predictably high oral absolute bioavailability in pigs (65-72%). T max values in pigs were 2.4-4.6 h, which were similar to estimates in humans. [97] The in vivo results from the pig provided a better insight into the performance of different lipid-based formulation classes, and enhanced the understanding on in vitro behaviour as well as the predictability of in vitro results. In addition, an in silico biopharmaceutical model was developed from this data to predict drug and lipid absorption during digestion of lipid based formulations, thereby supporting the utility of pigs in mechanistic studies involving lipidbased formulations. [98] In the case of fenofibrate, the pig model was also employed to compare novel mesoporous formulation to the commercially available nanosized Lipantil â Supra. Interestingly, the absolute bioavailability for nanosized Lipantil â Supra observed in pigs was 71%, which n.a.
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The mean c max is considerably higher for the experimental formulation when compared against Procardia XL Procardia XL tablet (Pfizer) [104] was similar to the reported human data of 69%. [69, 70] Also the range of t max in pigs matched the human data. [70, 71] It should also be noted that a recent study by Thomas et al. [100] exploring oral bioavailability of fenofibrate from a series of lipid-based formulations in minipigs indicated that fenofibrate absorption in minipigs was considerably delayed. t max of fenofibrate was 8 h (0.5-30 h) from lipidbased formulations.
[100] Furthermore, t max of the micronized commercially available Lipanthyl 200 M capsules was 24 h (8-72 h) . [100] This may reflect differences in the study design (e.g. fed/fasting conditions, which affect gastric emptying), but also differences related to the breed of pigs used in the two studies, that is, landrace and mini pigs, where the latter may display different pharmacokinetic properties for fenofibrate relative to humans and landrace pigs. [101] The pig model has also been widely used to assess in vivo performance of a range of modified release formulations, see Table 5 . For controlled release formulations, the mechanism of drug release is dependent on the rate of degradation of the polymer, which controls the extent of drug diffusion through the polymer matrix. They are developed with the aim to reduce the frequency of dosing with a short terminal elimination half-life and to minimise the degree of fluctuation in the drug's plasma concentration over the dosing intervals. It is likely that some of the difference in the GI physiology can influence the release and bioavailability of controlled-release dosage forms. From a physiological perspective, pigs seem to be a suited surrogate for humans when evaluating controlled release formulations as each intestinal section, that is, duodenum, jejunum, ilium and colon, is comparable. Furthermore, the bacterial flora of the colon is considered similar to man. [17, 23] For sustained release formulations, a few studies have been reported in the literature where the pig was used as an animal model. For formulations with glipizide, the pig was reported to be a suitable model to predict modified release formulation performance. Kulkarni et al. [102] reported that the porcine absorption kinetics were consistent with the published clinical data, conversely the beagle dog was less consistent compared to humans. Kostewicz et al. investigated nifedipine sustained formulations in pigs, as described in Table 5 , the obtained data were similar to data from a previously performed human study. Kostewicz et al. [104] came to the conclusion that the obtained results suggested that the pig can be a useful model in differentiating the release profiles of nifedipine for the fed state in humans. Another type of sustained release that has been tested in pigs is entero-coated formulations. An important factor for these kinds of systems is the pH in the stomach and the pH change upon entry into the small intestine. Pigs have a slower gastric emptying rate than humans, as discussed above; however, a very similar pH in the stomach and the small intestine. The study conducted with entero- (1) core: ocreotide, (2) conveyor system: super-porous hydrogel (SPH), (3) placed in enteric coated capsule (Eudragit S100) [107] coated formulations in pigs, therefore, resembled the release profile observed in humans well and pigs should in general be a suited model for evaluation of these systems. Although very limited data are available comparing different formulation systems in pigs, they all indicate that pigs can be useful when evaluating both sustained release formulations as well as bio-enabling formulations. This clearly demonstrates the relevance of the pig as a model to predict pharmacokinetics in human and the opportunity to use the pig for various formulation optimisation purposes.
Role of in vitro and in silico models for predicting the suitability of pig models and the gaps in the current knowledge A key driver of the drug and formulation development processes is the ability to predict human pharmacokinetics (PK) as early as possible, to select candidates with the best developability while rejecting those with a high probability of failure. [108] The intention of conducting in vivo preclinical studies in drug development is therefore to mitigate risk of developing medicines that are unsafe and/or ineffective in subsequent tests in humans, but equally important is to reduce the number of animals used for research purposes by appropriate application of in vivo studies. This is both an ethical and legislative obligation and the choice and number of animals has to be appropriately justified and must be in accordance with the 3 R's principle of replacement, reduction and refinement. In addition to the 'reduction' principle, 'replacement' options should always be considered, and this is where in vitro or in silico models can play a key role. Improvements in the correlation from in vitro data will help to reduce the number of animals needed. While the goal is to reduce the number of animals used, this reduction should not compromise the statistical outcome of the study, that is, an underpowered study, as it makes the data unsuitable for decision-making and therefore in principle unethical. Hence, the study should always include sufficient experimental units to obtain a precise and robust result that can lead to a correlation or prediction of the drug performance in humans.
Prediction of human pharmacokinetics generally relies on interpretation and extrapolation from in vitro and preclinical in vivo data. [41] There has been significant development in computational approaches to predict human pharmacokinetics, ranging from classical computational absorption simulation based on compartmental PK through to more complex physiologically based pharmacokinetic (PBPK) models, which can integrate data from both these sources to give an estimate of human PK. [109] A schematic presentation of the process is illustrated in Figure 8 . The application of in silico modelling, with a specific focus on the use in pigs is discussed below. 
Reliable in vitro methods: bio-relevant media
The first step to characterise the dissolution and solubility behaviour of a drug is reliable and appropriate in vitro models. [110] The selection of the media is a crucial step, and bio-relevant media simulating the human's gastrointestinal conditions is a useful tool to get a first impression of the dissolution properties of a drug. [111] More important, the aim to reduce the number of animals is to mimic the preclinical animal conditions. For common preclinical animal models, like dogs and rats, bio-relevant dissolution media has been developed to simulate the gastrointestinal tract fluids of these species. [112] Properties such as pH, buffer capacity, osmolality, surface tension and hydrodynamic conditions were included to improve forecast and interpretation of preclinical results. For the pig, the data are limited, there is a clear lack about the composition of porcine gastric and intestinal fluids; hence, no bio-relevant media is available for pigs why further work is needed to characterise intestinal porcine conditions. On the whole, media specially designed for preclinical animal models will be essential to guide the selection of animal species suited for in vivo investigations of a drug candidate.
Computational models and in vitro-in vivo correlations
The simplest methods for predicting in vivo results are by means of an in vitro-in vivo correlation (IVIVC). Kesisoglou et al. demonstrated the use of a simple level C IVIVC in a retrospective analysis of the in vivo performance of extended release matrix and multi-particulate preparations of a BCS class III development candidate (MK-0941) with different targeted release rates (8, 12 and 16 h) in Yucatan minipigs. A good correlation between the in vitro release and bioavailability was reported. [105] Similarly, Keohane et al. demonstrated an in vitro-in vivo relationship (IVIVR) for coated microspheres containing Cyclosporin A. The resultant IVIVR demonstrated a strong linear correlation between in vitro release and in vivo absorption. [82] McCarthy et al., meanwhile, demonstrated the possibility of obtaining a level A IVIVC using such an approach, by optimising the bio-relevance of the dissolution test for fenofibrate, as a model for poorly soluble compound. McCarthy et al. [70] demonstrated that computational in silico methods could be used to deconvolute the oral absorption process from the pharmacokinetic profile, correlate this with in vitro release and model in vivo pharmacokinetics by re-convolution. Govender et al. [113] have recently proposed a similar approach to describe the absorption of amoxicillin from a delayed release, dual-biotic system.
Computational models based on the release and distribution kinetics of drug from formulations, modelled along with compartmental PK, have also been implemented. Stillhart et al. [98] developed a pharmacokinetic model in MatLab, based on simulating the intraluminal concentration and solubility of fenofibrate when delivered in three distinct lipid-based formulations to fasted, juvenile Landrace pigs. Using this biopharmaceutical model, it was possible to accurately model plasma profiles, while also allowing a prediction of the intraluminal solubilisation, supersaturation and precipitation of the administered formulation. Using a model that considered the absorption of both the drug and lipid excipients after oral administration, it was possible to mechanistically investigate the in vivo performance in a manner not possible using simple in vitro digestion tests, which do not consider the impact of continuous absorption. [98] Physiologically based pharmacokinetic models
The distinguishing feature of PBPK models, relative to empirical computational models, is the application of prior physiological knowledge in the mechanistic mapping of model compartments and in the processes that determine absorption. [41, 104] This physiological knowledge, incorporating parameters such as gastrointestinal transit, pH and luminal volume, is combined with physiochemical measurements, for example, dissociation constants and partition coefficients, and in vitro measurements, such as solubility and dissolution rates and enzymatic degradation kinetics, into the PBPK model to provide a simulated PK profile. [41, 109, 114] PBPK models allow predictions of drug disposition based on a series of mass-balance equations, which incorporate physiological, physiochemical and in vitro data within an in silico model. [115] Numerous commercial PBPK software systems are available, most notably Simcyp, GastroPlus TM and PK-Sim â , while there is also widespread use of user-built models, built using packages such as MATLAB . [114] Physiologically based pharmacokinetic has a long history of use in veterinary pharmacology and toxicology. These studies have a particular focus on analysing xenobiotic disposition for the purposes of estimation of meat withdrawal periods based on residue depletion in edible tissue after either accidental exposure to a toxin or after off-label use of a veterinary preparation. Numerous reports of PBPK models being used to extrapolate disposition studies between species, [115] [116] [117] [118] [119] estimate withdrawal periods based on probabilistic methods [120, 121] and assessment of the potential for drug-drug interactions due to altered protein binding [122, 123] have been published.
The growing use of the pig as a preclinical species of choice has led to significant developments in porcine PBPK models. Jones et al. [108] developed a generic PBPK model for the prediction of clinical pharmacokinetics using preclinical data from various sources, including pigs, which proved superior to allometric scaling. While significant differences remained in some cases, particularly when certain assumptions of the PBPK model were violated, the use of PBPK modelling provided insight into potential reasons for poor predictability, which allometric methods did not. [108] The most significant development in PBPK modelling in pigs was the minipig PBPK model developed using the advanced compartmental absorption (ACAT) model. Using a series of mass-balance equations that describe the specific physiology of the minipig, a porcine PBPK model was generated to simulate oral PK. The proposed model was initially validated with griseofulvin and moxifloxacin, with encouraging results. [41] However, the authors also identified areas where this model can further be refined, particularly in the areas of absorption-related parameters and bile salt profiles within the minipig intestine. Further physiological characterisation along with pharmacokinetic analysis of well-chosen reference compounds, and adjustment of the model to reflect in vivo PK, was suggested to contribute to model refinement. [41] Subsequent work using paracetamol as a marker of GI motility and gastric emptying was used to update this model. The updated model was subsequently validated on a number of PK studies in minipigs using omeprazole, caffeine, midazolam and warfarin. The prolonged gastric emptying in the re-parameterised PBPK model accurately predicted pharmacokinetics of this validation data-set in minipigs. [44] Studies such as those by Lignet et al. [86] can further add to this knowledge space, aiding the development and validation of this PBPK model by characterising the bioavailability of a set of reference compounds in the minipig model. O'Shea et al. [99] used the GastroPlus TM minipig ACAT PBPK model to simulate bioavailability of fenofibrate from a commercial micronized formulation and novel lipidbased formulation in fasted landrace pigs. Using this model, the authors successfully simulated fasted bioavailability for both formulations by incorporating the intravenous pharmacokinetic data, along with bio-relevant in vitro solubility and dissolution measures into the mechanistic model. The model was subsequently used to extrapolate this data to the fed state, where the elimination of a food-dependent increase in fenofibrate bioavailability utilising the novel formulation was predicted. [99] Kesisoglou et al. [124] have also used the GastroPlus TM minipig model, in conjunction with modelling of dog and human data, in the formulation development of a modified release preparation of gaboxadol. The authors successfully incorporated in vitro dissolution data and preclinical pharmacokinetic data within the PBPK models to guide formulation development. Subsequently, it was possible to use the minipig PBPK model to develop an IVIVC to project formulation performance. [124] Using regional permeability data measured in dogs and clinical pharmacokinetics from human studies, the minipig ACAT model was optimised using an immediate release dry filled capsule as a reference. Using this optimised model, the in vivo dissolution was deconvoluted from the simulated plasma profile for two modified release formulations. This in vivo dissolution profile was subsequently plotted against the in vitro release profile resulting in a linear IVIVC. [124] Lennern€ as et al. have also developed porcine PBPK models, with a particular focus on simulating data from Landrace and Yorkshire pigs, which have multiple blood sampling sites. By measuring plasma concentrations in the hepatic, portal and femoral veins, along with biliary and urinary concentration, a detailed analysis of the ADME process was obtained. [125] Sj€ ogren et al. developed 11 compartment PBPK pig model, to model drug concentrations in these sampling sites and estimate tissue distribution throughout a whole-body PBPK model. This mechanistic PBPK model, in combination with appropriate in vitro assessment of enzyme kinetics and cellular disposition, allowed successful prediction of the influence of metabolism and carrier-mediated processes on the hepatic disposition of repaglinide. [125] Similar models were used by Lennern€ as et al. [126] to investigate a potential drug-drug interaction between verapamil and fexofenadine and to mechanistically investigate the effect of intracellular binding of doxorubicin on its PK in pigs. [127] The use of PBPK modelling during drug and formulation development is an emerging field for the prediction of preclinical and clinical PK using physiochemical and in vitro measurements. However, thus far the use of PBPK modelling has been largely confined to the retrospective, mechanistic analysis of preclinical data. While some work has focused on the extrapolation of these models to alternative formulations or dosing scenarios (e.g. in fed vs fasted state), and extrapolating between different preclinical species, there is still a lack of prospective models used in formulation design. There remains a need for systematic studies utilising PBPK models as part of a 'learn and confirm' paradigm before the full benefit of this approach is realised.
Conclusion
This review has investigated the potential advantage and suitability of the pig as a preclinical model within pharmaceutical sciences. From an anatomical and physiological perspective, the pig model is widely recognised and displays high similarities to the GI conditions of humans. There remain striking gaps in our knowledge about the pig model and its utility to predict human bioavailability of oral dosage forms, as discussed above. Analysis of the available literature for absolute bioavailability studies conducted in pigs, dogs and humans demonstrated that the pigs compared favourably to dogs in terms of predicting human bioavailability.
As a result of the limited data available in the literature, it is currently not possible to make quantitatively predictions of human bioavailability.
While this review has provided specific examples of limitation of pigs, such as drugs metabolised extensively by the CYP2D system, there is overall a need to harness knowledge from a wider range of drug molecules (both successes and failures) to develop better guides as to which drug formulation that are best suited for testing in pigs. There is also an opportunity to improve the link between in vitro screening and in vivo testing in preclinical animals. This could be the development of species-specific bio-relevant screening tool, which is currently not available for pigs.
Clearly, there is no 'one size fits all' choice in the context of preclinical animal modelling; hence, there is no 'ideal' species that represent all aspects of human GI conditions. [9] With the data presented in the present work, it is reasonable to state that the pig model is similar to most physiological conditions in man and hence a model suitable for considering when conducting in vivo studies.
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